Skip to main content

Table 2 Current and prior meta-analyses comparing hMG versus r-hFSH

From: Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis

  Al-In, 2003 Al-In, 2005 Al-In, 2008 Al-In, 2009 Coom 2008 West, 2003 Sponsor Paper Chalmers nhMG nr-hFSH
Duijkers, 1997 [46] 0 0 0 0 0 0 0 1 58 7 6
Jansen et al. 1998 [19] 0 1 1 0 0 1 1 1 72 35 54
Kornilov et al. 1999 [20] 0 0 0 0 0 1 0 1 67 40 28
Serhal et al. 2000 [21] 0 0 0 0 0 1 0 0 60 144 94
Ng et al. 2001 [16] 1 1 1 0 1 1 0 1 56 20 20
Strehler et al. 2001 [22] 0 1 1 0 0 1 0 1 67 248 259
Westergaard et al. 2001 [17] 1 1 1 0 1 1 1 1 64 189 190
Gordon et al. 2001 [15] 1 1 1 0 1 1 0 1 63 29 39
European and Israeli Study Group 2002 [14] 1 1 1 1 1 1 1 1 71 357 336
Kilani et al. 2003 [25] 0 1 1 1 1 0 1 1 67 50 50
Balasch et al. 2003 [24] 0 1 1 0 1 0 1 1 65 25 25
Rashidi et al. 2005 [29] 0 0 1 0 0 0 0 1 72 30 30
Andersen et al. 2006 [5] 0 0 1 1 1 0 1 1 77 363 368
Hompes et al. 2008 [28] 0 0 1 1 0 0 1 1 76 312 317
Bosch et al. 2008 [27] 0 0 1 1 0 0 1 1 57 122 126
Ruvolo et al. 2009 [47] 0 0 0 0 0 0 0 0 52 10 19
  1. 16 studies identified from the literature search, compared with previous meta-analyses. The first 6 columns compared the referenced meta-analyses using the following definitions: sponsor, whether or not the study was funded by a pharmaceutical company; paper, whether a peer-reviewed publication or abstract only was available; Chalmers, the Chalmers internal validity mean score [29]. The last two columns are the sample sizes for each study.